U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Training and Continuing Education
  3. Guidance Webinar Series
  4. FDA Webinar: Draft Guidance: Use of an Electronic Informed Consent in Clinical Investigations Questions and Answers – April 20, 2015
  1. Guidance Webinar Series

FDA Webinar: Draft Guidance: Use of an Electronic Informed Consent in Clinical Investigations Questions and Answers – April 20, 2015

On Monday, April 20, 2015, the Office of Medical Policy (OMP) in the Center for Drug Evaluation and Research (CDER), presented a webinar on the Draft Guidance: Use of an Electronic Informed Consent in Clinical Investigations Questions and Answers.
Summary: The Food and Drug Administration is announcing the availability of a draft guidance entitled “Use of Electronic Informed Consent in Clinical Investigations: Questions and Answers.” The purpose of this guidance is to provide recommendations for clinical investigators, sponsors, and institutional review boards (IRBs) on the use of electronic media and processes to obtain informed consent for FDA-regulated clinical investigations of medical products, including human drug and biological products, medical devices, and combinations thereof.
 
Documents:
 
 
Federal Register Publication Date:     03/09/2015
 
Comments Date:     05/08/2015
 
Docket Number:     FDA-2015-05377
 
Speakers:
Leonard V. Sacks, M.D.
Associate Director for Clinical Methodology
OMP/CDER/FDA
 
Cheryl A. Grandinetti, Pharm.D.
Health Scientist Policy Analyst
OMP/CDER/FDA

 

Back to Top